Australian health company, Wellnex Life (ASX: WNX) has secured a pivotal partnership and received its first purchase order from global provider Haleon to supply Paracetamol Soft Gel Liquid Analgesic to the UK market. In today’s health-conscious world where consumers demand innovative and effective solutions, Wellnex Life’s partnership with Haleon positions the Company at the forefront to meet these increasing demands. 

After the successful product launch in Australia during FY23 and debut in the United Arab Emirates, the Company intends to target high-demand markets aligned with global health trends which will lay out a path for Wellnex to nail the hook on significant market share.

Haleon, a global provider in consumer healthcare, is committed to enhance everyday health for millions worldwide. Boasting a strong portfolio of trusted brands like Panadol and Sensodyne, the Company focuses on oral health, vitamins, minerals, and supplements, and over-the-counter medications, including pain relief, respiratory, digestive, and other solutions. 

The Company focuses on identifying and developing healthcare products that meet stringent regulatory standards, like those set by the Therapeutic Goods Administration in Australia. By owning the intellectual property and brands for these products, Wellnex can ensure consistent quality and maintain market exclusivity, which is crucial in preventing competitors from copying their innovations. 

Wellnex’s expansion into the UK aims to capitalise on the growing emphasis on wellness and self-care. This joint venture allows Wellnex’s entry into one of Europe’s largest and most competitive healthcare markets. This will allow the Company to utilise Haleon’s widespread distribution channels which will increase brand visibility in the UK healthcare market. 

This approach allows Wellnex to provide high-quality solutions in both local and international markets, while also creating opportunities for additional revenue streams through licensing and increasing their global footprint. 

Zack Bozinovski, Director of Wellnex, said “The launch with Haleon for the UK market for our TGA registered paracetamol soft gel liquid analgesic for one of Europe’s largest markets is an important milestone for the Company. 

“The trust and confidence imparted upon Wellnex to supply one of the world’s leading pain relief brands in Panadol is a validation and testament to our Wellnex Life’s business model.” 

For the quarter ended 30 June 2024, the Company reported $4.9 million in cash receipts, representing a 56% increase on the March quarter. This resulted in a negative operating cash flow of $1.4 million, bringing the nine-month YTD operating cash outflow to $4.8 million. 

As of 30 June 2024, the Company had $1.04 million cash in reserves.